Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
AffiliationDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX England, UK.
MetadataShow full item record
AbstractAngiogenesis is believed to play a critical role in cancer; however, antiangiogenic therapy has not been demonstrated to improve the survival of patients who have lung cancer. In this article, the evidence that supports a role for angiogenesis in the pathogenesis of lung cancer, trials of antiangiogenic agents in lung cancer performed to date, and the lessons learned from these studies are discussed.
CitationAngiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer. 2004, 18 (5):1121-41, Hematol. Oncol. Clin. North Am.
JournalHematology/Oncology Clinics of North America
- Angiogenesis and antiangiogenic agents in non-small cell lung cancer.
- Authors: Galligioni E, Ferro A
- Issue date: 2001 Dec
- [The actual place of anti-angiogenesis in non-small cell lung cancer].
- Authors: Mennecier B
- Issue date: 2007 Oct
- Antiangiogenic therapy in nonsmall cell lung cancer.
- Authors: Gutierrez M, Giaccone G
- Issue date: 2008 Mar
- Targeting blood vessels for the treatment of non-small cell lung cancer.
- Authors: Amir E, Hughes S, Blackhall F, Thatcher N, Ostoros G, Timar J, Tovari J, Kovacs G, Dome B
- Issue date: 2008 Aug
- [Angiogenesis and lung cancer].
- Authors: Pérol M, Arpin D
- Issue date: 2007 Jul